Alzheimers

Lecanemab Linked to Lower Neuropsychiatric Symptoms in Alzheimer’s

July 11, 2026 by BrainASAP

TL;DR: A 2026 real-world cohort study in The Journal of Prevention of Alzheimer’s Disease found that lecanemab-treated Alzheimer’s patients had lower Neuropsychiatric Inventory scores over follow-up, and 6-month symptom reductions were associated with regional amyloid-beta positron emission tomography (PET) clearance. Key Findings 144 treated patients: The cohort included people with Alzheimer’s-related mild cognitive impairment or …

Review Identified Different Depression Treatment Targets in Alzheimer’s and Parkinson’s

July 10, 2026 by BrainASAP

TL;DR: A 2026 narrative review in Molecular Psychiatry argues that depression in Alzheimer’s disease and Parkinson’s disease follows disease-specific brain mechanisms, while standard antidepressant evidence remains weak in these neurodegenerative populations. Key Findings 42% in Alzheimer’s disease: The review cites depressive syndromes affecting about 42% of patients with Alzheimer’s disease and 35% of patients with …

Tubulin Shifted Tau and Alpha-Synuclein Condensates Toward Microtubules

July 9, 2026 by BrainASAP

TL;DR: A 2026 study in Nature Communications reported that tubulin redirected Tau and alpha-synuclein condensates toward microtubule-building states, while tubulin loss pushed the same protein system toward toxic oligomers in cell models. Key Findings 36-hour shift: Tau and alpha-synuclein condensates formed stable high-molecular-weight oligomers and Tau:alpha-synuclein heterodimers after aging without tubulin. 10-micromolar tubulin: Adding tubulin …

Karyoptosis Linked Proteotoxic Stress to Neurodegeneration

July 9, 2026July 9, 2026 by BrainASAP

TL;DR: A 2026 study in Nature Communications found that proteotoxic stress can push neurons into karyoptosis, a cell-death pathway marked by nuclear lamina breakdown, nuclear-material expulsion, and dementia-linked tissue signatures. Key Findings Karyoptosis was induced by protein-clearance stress: Blocking autophagic lysosomal clearance caused LaminB1 disruption, nuclear-shape loss, cytoplasmic nuclear material, and later cell death. p38-LaminB1 …

Brain-Derived Plasma pTau217 Better Predicted Near-Term Amyloid PET Progression

July 9, 2026 by BrainASAP

TL;DR: A 2026 ADNI analysis posted to medRxiv found that brain-derived plasma pTau217 better predicted near-term amyloid positron emission tomography (PET) positivity than total plasma pTau217 in cognitively unimpaired amyloid-negative participants. Key Findings 1,427 ADNI participants: Plasma NULISAseq biomarkers were measured across the broader Alzheimer’s Disease Neuroimaging Initiative sample. 529 cognitively unimpaired: The main prognostic …

Diclofenac and Naproxen Use Linked to Lower Dementia Prevalence in NACC Cohort

July 9, 2026 by BrainASAP

TL;DR: A 2026 retrospective analysis posted to medRxiv linked diclofenac and naproxen use in the NACC cohort to lower dementia and Alzheimer disease prevalence, while diclofenac use was also associated with slower Montreal Cognitive Assessment (MoCA) cognitive-screening decline. Key Findings NACC cohort: The analysis used 47,165 National Alzheimer’s Coordinating Center participants with data collected from …

Japan Dementia Specialist Survey Protocol Mapped Anti-Amyloid Antibody Bottlenecks

July 8, 2026 by BrainASAP

TL;DR: A 2026 protocol posted to medRxiv describes a nationwide Japan survey designed to measure how dementia specialists handle anti-amyloid antibody therapy, biomarker testing, MRI safety monitoring, service capacity, and patient-choice tradeoffs. Key Findings Nationwide specialist survey: The protocol targets board-certified dementia specialists in Japan, especially physicians trained for anti-amyloid antibody therapy. June 2026 data …

6PPD-Quinone Linked to Alzheimer’s Disease Pathways in Network Analysis

July 7, 2026 by BrainASAP

TL;DR: A 2026 study in Open Medicine used network pharmacology, Alzheimer’s disease transcriptomic datasets, machine learning, Mendelian randomization, and molecular docking to link 6PPD-quinone, a tire-wear chemical transformation product, with inflammation, oxidative-stress, kinase-signaling, and synaptic pathways relevant to Alzheimer’s disease. Key Findings 92 overlapping targets: Database mining found 92 molecular targets shared between 6PPD-quinone and …

BCG Immunotherapy Altered CNS Immunity and Alzheimer’s Biomarkers

July 7, 2026 by BrainASAP

TL;DR: A 2026 open-label study in Communications Medicine found that Bacillus Calmette-Guerin (BCG) immunotherapy changed cerebrospinal-fluid immune-cell responses and Alzheimer-related biomarkers in 23 older adults. Key Findings Small trial context: 2 related 1-year open-label trials enrolled 23 adults aged 55 or older at one academic medical center. BCG dosing was simple: Participants received 2 intradermal …

Hyperglycosylation Linked Glucosamine to Faster Alzheimer Progression

July 4, 2026 by BrainASAP

TL;DR: A 2026 study in Nature Metabolism identified brain hyperglycosylation as a metabolic driver of Alzheimer disease in human tissue and mouse models, while glucosamine exposure was linked to worse outcomes in Alzheimer-related dementia records. Key Findings Human AD brains showed excess glycans: Spatial glycomics found elevated N-glycan abundance in Alzheimer frontal cortex samples compared …

+ Load more